ERBB2 and breast carcinoma: In our study population of 133 cases of male breast cancer, we found 4 cases (3.0%) expressing HER2, 15 cases (11.4%) EGFR, 6 cases (4.5%) MET, 16 cases (12.1%) FGFR2, and 50 cases (38.5%) IGF1-R (Table 2).